EBRO 2017

NCT01603420

Proton Collaborative Group Primary endpoint: 5-year Freedom From Failure (FFF) Rates

RT 79.2 Gy(RBE)+ ADT 24 m.

Random

RT 79.2 Gy(RBE) + ADT 6 m. + Weekly Docetaxel (20mg/m2 IV)

Trial is completed. Results are pending